Navigation Links
Masimo to Report Fourth Quarter and Full Year 2012 Financial Results after Market Close on Thursday, February 14
Date:1/30/2013

IRVINE, Calif., Jan. 30, 2013 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today that it will release fourth quarter and full year 2012 financial results for the period ended December 29, 2012, after the market closes on Thursday, February 14, 2013. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani , Chairman and Chief Executive Officer, and Mark P. de Raad , Executive Vice President and Chief Financial Officer.

A live webcast of the conference call will be available online from the investor relations page of the company's corporate website at www.masimo.com. The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers. The reservation code for both dial-in numbers is 92598385. After the live webcast, the call will be available on Masimo's website through March 14, 2013. In addition, a telephonic replay of the call will be available through February 28, 2013. The replay dial-in numbers are (800) 585-8367 for domestic callers and +1 (855) 859-2056 for international callers. Please use reservation code 92598385.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. And in 2012, Masimo acquired the assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Contact:
Sheree Aronson
(949) 297-7043
saronson@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine  are trademarks or registered trademarks of Masimo Corporation.


'/>"/>
SOURCE Masimo Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Masimo Showcases Advanced, Noninvasive Patient Monitoring Technologies at Arab Health
2. Masimo Reports Third Quarter 2012 Financial Results; Board Declares Special Cash Dividend of $1.00 per Share
3. Masimo to Present at Lazard Capital Markets 9th Annual Healthcare Conference
4. Kennedy Health System Renews System-Wide Pulse Oximetry Contract with Masimo
5. Masimo Reschedules Release of Third Quarter 2012 Financial Results and Associated Conference Call to Thursday, November 1st Due to Hurricane Sandy
6. Inova Health System Re-Ups System-wide Pulse Oximetry Contract with Masimo
7. Masimo to Host Investor Day on September 20
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Masimo Corporation in Connection with Executive Compensation
9. Masimos Noninvasive Pleth Variability Index as Accurate as Invasive Stroke Volume Variation for Fluid Responsiveness Assessment in Cardiac Surgery
10. Masimo Enters Noninvasive Multigas Monitoring, including Capnography, with Acquisition of PHASEIN
11. Masimo Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... ... possible to see through objects, has announced the winners of its "Power to ... its fully programmable, Raspberry Pi-enabled 3D sensor, Walabot . Creators cast submissions ...
(Date:6/28/2017)... NE (PRWEB) , ... June 28, 2017 , ... ... Medical has been recognized for excellence in employee engagement. Omaha-based C&A ... the Achievers 50 Most Engaged Workplaces™ in North America for 2017. ...
(Date:6/28/2017)... ... June 28, 2017 , ... Guide to FDA and ... , No matter on which side of the Atlantic devicemakers do business, this fully ... have to follow. , In addition to the full text of the FDA’s regulations ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest ... minutes, at least one person dies as a direct result from an eating disorder ... for qualified treatment providers. The iaedp Foundation meets this challenge by offering what has ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the participation ... award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs Tuesdays ... regional supplier of garden pea seed. As demand grew, the small company located in ...
Breaking Medicine News(10 mins):